<div id="readability-page-1"><p>Gabelli Funds LLC cut its position in shares of  AbbVie Inc. (NYSE:ABBV - Free Report) by 6.2% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 100,963 shares of the company's stock after selling 6,700 shares during the period. Gabelli Funds LLC's holdings in AbbVie were worth $23,377,000 as of its most recent SEC filing.</p><ul><li>Quiet Outperformance From an Overlooked Dividend ETF</li></ul><p>Several other institutional investors have also added to or reduced their stakes in ABBV. Evolution Wealth Management Inc. purchased a new position in shares of  AbbVie in the second quarter valued at $26,000.  Caitlin John LLC purchased a new stake in  AbbVie during the third quarter valued at $33,000.  Redmont Wealth Advisors LLC purchased a new stake in  AbbVie during the third quarter valued at $41,000.  Financial Gravity Companies Inc. bought a new position in  AbbVie during the second quarter valued at $36,000.  Finally, Delos Wealth Advisors LLC purchased a new position in shares of  AbbVie in the 2nd quarter worth $39,000. Hedge funds and other institutional investors own  70.23% of the company's stock. </p><h2>Analysts Set New Price Targets</h2><p>A number of research firms have recently weighed in on ABBV. Weiss Ratings  restated a &#34;hold (c)&#34; rating on shares of AbbVie in a report on Wednesday, January 21st. Morgan Stanley lifted their price target on AbbVie from $269.00 to $270.00 and gave the stock an &#34;overweight&#34; rating in a research report on Thursday, February 5th. Evercore reduced their price objective on AbbVie from $232.00 to $228.00 and set an &#34;outperform&#34; rating on the stock in a research note on Wednesday, February 4th. Piper Sandler upped their price objective on AbbVie from $289.00 to $299.00 and gave the company an &#34;overweight&#34; rating in a research report on Wednesday, February 18th. Finally, Royal Bank Of Canada began coverage on AbbVie in a research note on Tuesday, February 24th. They issued an &#34;outperform&#34; rating and a $260.00 price objective for the company. Two research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and nine have given a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $253.15.</p><ul><li>These 3 Cash Flow Machines Provide Stability in Uncertain Markets</li></ul><p><b>Check Out Our Latest Analysis on ABBV</b></p><h2>AbbVie Trading Down 0.8%</h2><p>ABBV stock opened at $230.41 on Friday. The stock has a market cap of $407.40 billion, a PE ratio of 97.63, a P/E/G ratio of 0.80 and a beta of 0.34. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The company has a 50-day moving average price of $224.72 and a 200 day moving average price of $224.10. </p><ul><li>AbbVie’s Prognosis: The February Dip Looks Like a Buy Signal</li></ul><p>AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings data on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 1,579.75%. The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same period in the prior year, the company posted $2.16 EPS. The firm's revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS.  Sell-side analysts forecast that  AbbVie Inc. will post 12.31 EPS for the current year. </p><h2>AbbVie Dividend Announcement</h2><p>The firm also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be paid a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend is Wednesday, April 15th. AbbVie's dividend payout ratio (DPR) is currently 293.22%. </p><h2>Insiders Place Their Bets</h2><p>In other AbbVie news, EVP Perry C. Siatis sold 22,381 shares of the company's stock in a transaction on Wednesday, February 25th. The stock was sold at an average price of $230.00, for a total value of $5,147,630.00. Following the transaction, the executive vice president owned 38,137 shares of the company's stock, valued at $8,771,510. This represents a 36.98% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, SVP David Ryan Purdue sold 5,230 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $233.56, for a total value of $1,221,518.80. Following the completion of the sale, the senior vice president owned 2,654 shares in the company, valued at approximately $619,868.24. The trade was a 66.34% decrease in their position. The disclosure for this sale is available in the SEC filing. 0.25% of the stock is owned by insiders. </p><h2>Key AbbVie News</h2><p>Here are the key news stories impacting AbbVie this week:</p><ul>   <li><span>Positive Sentiment: </span>Q4 beat and raised FY/Q1 outlook — AbbVie posted better‑than‑expected Q4 EPS and revenue and gave FY‑2026 guidance (14.37–14.57 EPS), supporting the bull case for continued top‑line and EPS growth. <i></i><span>AbbVie (ABBV): Buy, sell, or hold post Q4 earnings?</span></li>    <li><span>Positive Sentiment: </span>Pipeline catalysts: neuroscience momentum and new approvals could drive revenue — the neuroscience unit generated ~$10.8B in 2025 and analysts see upside to ~$12.5B in 2026 as Vyalev ramps and tavapadon awaits FDA review. <i></i><span>Will AbbVie's Neuroscience Segment Continue to Aid Top Line in 2026?</span></li>    <li><span>Positive Sentiment: </span>Positive Phase‑3 SKYRIZI Crohn’s data strengthens the immunology franchise and expands commercial potential for risankizumab. This data is a material upside to long‑term revenue expectations for immunology products. <i></i><span>Did Positive Phase 3 SKYRIZI Crohn’s Data Just Shift AbbVie’s (ABBV) Immunology Investment Narrative?</span></li>    <li><span>Neutral Sentiment: </span>Analyst/market attention: some bullish writeups call ABBV a core, buy‑and‑hold dividend name and note the stock has rallied since earnings — supportive for sentiment but already reflected in recent gains. <i></i><span>AbbVie: The only big pharma stock I'd consider a buy-and-never-sell</span></li>    <li><span>Neutral Sentiment: </span>Operational investment: AbbVie will spend $380M to expand its North Chicago campus — a long‑term capacity/R&amp;D bet that supports future growth but increases near‑term capex. <i></i><span>AbbVie to invest $380 million in North Chicago campus to make next generation medicines</span></li>    <li><span>Negative Sentiment: </span>Debt issuance: AbbVie completed an $8B senior notes offering, which increases leverage and raises capital‑structure risk that investors may price in, especially given the company’s already elevated payout metrics. <i></i><span>AbbVie Completes $8 Billion Senior Notes Financing Offering</span></li>    <li><span>Negative Sentiment: </span>Dividend and leverage concerns: analysts caution that a very high payout ratio and significant debt levels warrant caution for income investors despite strong free cash flow. That raises risk of multiple compression if growth slows. <i></i><span>Dividend Stock Analysis - Abbvie Inc.</span></li>    <li><span>Negative Sentiment: </span>Near‑term price pressure: recent sessions show ABBV underperforming the wider market on profit‑taking and macro moves, which can amplify volatility after the post‑earnings run. <i></i><span>AbbVie (ABBV) Suffers a Larger Drop Than the General Market: Key Insights</span></li> </ul><h2>About AbbVie</h2> (Free Report)<p>AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.  </p><p>AbbVie's product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women's health.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than AbbVie</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Trump Planning to Use Public Law 63-43: Prepare Now</li><li>How JPMorgan's $8,000 Gold Call Will Leave Most Retirement Accounts Behind</li><li>Silver Is the New Oil—And the World’s Running Dry</li><li>Nvidia CEO Issues Bold Tesla Call</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUFCQlY"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in AbbVie Right Now?</h2><p>Before you consider AbbVie, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AbbVie wasn't on the list.</p><p>While AbbVie currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LABD

ABBV

<p>Gabelli Funds LLC has reduced its stake in AbbVie Inc. (NYSE:ABBV) by 6.2%, now holding 100,963 shares valued at $23.38 million. Other institutional investors have also adjusted their positions in AbbVie. Analysts have mixed ratings on the stock, with a consensus price target of $253.15. AbbVie recently reported earnings of $2.71 per share, exceeding estimates, and declared a quarterly dividend of $1.73 per share, yielding 3.0%. The stock is currently trading at $230.41, down 0.8%.</p>

Market Beat

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bear 3X

Abbvie

Proshares Ultra Nasdaq Biotech

Invesco Biotechnology & Genome ETF

Ark Genomic Revolution ETF

Health Care Select Sector SPDR

iShares Biotechnology ETF

iShares US Pharma

ALPS Medical Breakthrough

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

VG Health

SPDR S&P Biotech

Gabelli Funds LLC Decreases Stake in AbbVie Inc. $ABBV